Community-associated extended-spectrum -lactamase-producing Escherichia coli infection in the United States

Clinical Infectious Diseases

Volumn 56, Issue 5, 2013, Pages 641-648

  Doi, Yohei ^a   Park, Yoon Soo ^a,b   Rivera, Jesabel I ^a   Adams Haduch, Jennifer M ^a   Hingwe, Ameet ^c   Sordillo, Emilia M ^d   Lewis, James S ^e   Howard, Wanita J ^f   Johnson, Laura E ^c   Polsky, Bruce ^d   Jorgensen, James H ^e   Richter, Sandra S ^g   Shutt, Kathleen A ^a   Paterson, David L ^a,h  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b Gachon University   (South Korea)

^c Henry Ford Health System Division of Infectious Diseases   (United States)

^d ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^f UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^g LERNER RESEARCH INSTITUTE   (United States)

^h UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

community associated infection; Escherichia coli; extended spectrum beta lactamase (ESBL)

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZTREONAM; BETA LACTAMASE AMPC; BETA LACTAMASE CTX M; BETA LACTAMASE SHV; CEFEPIME; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; CLAVULANIC ACID; COTRIMOXAZOLE; DORIPENEM; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; MINOCYCLINE; NITROFURANTOIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TETRACYCLINE; TIGECYCLINE; TIMENTIN; TOBRAMYCIN;

ABSCESS; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; CARDIOVASCULAR DISEASE; CHOLECYSTITIS; CHRONIC KIDNEY FAILURE; COMMUNICABLE DISEASE; COMMUNITY HOSPITAL; CYSTITIS; DEMENTIA; EPIDEMIC; ESCHERICHIA COLI INFECTION; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI INFECTION; FEMALE; FUNGAL STRAIN; HEALTHCARE ASSOCIATED INFECTION; HOSPITALIZATION; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MICROBIAL SENSITIVITY TEST; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OUTPATIENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PYELONEPHRITIS; RISK ASSESSMENT; SEQUENCE ANALYSIS; SOLID TUMOR; UNITED STATES; UNIVERSITY HOSPITAL; URINARY TRACT INFECTION;

BETA-LACTAMASES; COMMUNITY-ACQUIRED INFECTIONS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HUMANS; PROSPECTIVE STUDIES; RISK FACTORS; UNITED STATES;

EID: 84873638279     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis942     Document Type: Article

References (38)

1. Paterson DL, Bonomo RA. Extended-spectrum ?-lactamases: a clinical update. Clin Microbiol Rev 2005; 18:657-86.
2. Bush K, Fisher JF. Epidemiological expansion, structural studies, and clinical challenges of new ?-lactamases from gram-negative bacteria. Annu Rev Microbiol 2011; 65:455-78.
3. Carattoli A. Resistance plasmid families in Enterobacteriaceae. Antimicrob Agents Chemother 2009; 53:2227-38.
4. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18:268-81.
5. David MZ, Daum RS. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev 2010; 23:616-87.
6. Ben-Ami R, Rodriguez-Bano J, Arslan H, et al. A multinational survey of risk factors for infection with extended-spectrum ?-lactamase-producing Enterobacteriaceae in nonhospitalized patients. Clin Infect Dis 2009; 49:682-90.
7. Pitout JD, Gregson DB, Church DL, Elsayed S, Laupland KB. Community-wide outbreaks of clonally related CTX-M-14 ?-lactamaseproducing Escherichia coli strains in the Calgary health region. J Clin Microbiol 2005; 43:2844-9.
8. Rodriguez-Bano J, Navarro MD, Romero L, et al. Epidemiology and clinical features of infections caused by extended-spectrum ?-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol 2004; 42:1089-94.
9. Johnson JR, Urban C, Weissman SJ, et al. Molecular epidemiological analysis of Escherichia coli sequence type ST131 (O25:H4) and blaCTX-M-15 among extended-spectrum-?-lactamase-producing E. coli from the United States, 2000 to 2009. Antimicrob Agents Chemother 2012; 56:2364-70.
10. Rogers BA, Sidjabat HE, Paterson DL. Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. J Antimicrob Chemother 2011; 66:1-14.
11. Cheong HS, Kang CI, Kwon KT, et al. Clinical significance of healthcare-associated infections in community-onset Escherichia coli bacteraemia. J Antimicrob Chemother 2007; 60:1355-60.
12. Friedman ND, Kaye KS, Stout JE, et al. Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 2002; 137:791-7.
13. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008; 36: 309-32.
14. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 20th informational supplement. Wayne, PA: CLSI, 2010.
15. Park YS, Adams-Haduch JM, Shutt KA, et al. Clinical and microbiologic characteristics of cephalosporin-resistant Escherichia coli at three centers in the United States. Antimicrob Agents Chemother 2012; 56:1870-6.
16. Clermont O, Dhanji H, Upton M, et al. Rapid detection of the O25b-ST131 clone of Escherichia coli encompassing the CTX-M-15-producing strains. J Antimicrob Chemother 2009; 64:274-7.
17. Wirth T, Falush D, Lan R, et al. Sex and virulence in Escherichia coli: an evolutionary perspective. Mol Microbiol 2006; 60:1136-51.
18. Robberts FJ, Kohner PC, Patel R. Unreliable extended-spectrum ?-lactamase detection in the presence of plasmid-mediated AmpC in Escherichia coli clinical isolates. J Clin Microbiol 2009; 47:358-61.
19. Sidjabat HE, Paterson DL, Adams-Haduch JM, et al. Molecular epidemiology of CTX-M-producing Escherichia coli isolates at a tertiary medical center in western Pennsylvania. Antimicrob Agents Chemother 2009; 53:4733-9.
20. Dias RC, Moreira BM, Riley LW. Use of fimH single-nucleotide polymorphisms for strain typing of clinical isolates of Escherichia coli for epidemiologic investigation. J Clin Microbiol 2010; 48:483-8.
21. Sader HS, Farrell DJ, Jones RN. Tigecycline activity tested against multidrug-resistant Enterobacteriaceae and Acinetobacter spp. isolated in US medical centers (2005-2009). Diagn Microbiol Infect Dis 2011; 69:223-7.
22. Woodford N, Kaufmann ME, Karisik E, Hartley JW. Molecular epidemiology of multiresistant Escherichia coli isolates from communityonset urinary tract infections in Cornwall, England. J Antimicrob Chemother 2007; 59:106-9.
23. Minarini LA, Gales AC, Palazzo IC, Darini AL. Prevalence of communityoccurring extended spectrum ?-lactamase-producing Enterobacteriaceae in Brazil. Curr Microbiol 2007; 54:335-41.
24. Kang CI, Cheong HS, Chung DR, et al. Clinical features and outcome of community-onset bloodstream infections caused by extendedspectrum ?-lactamase-producing Escherichia coli. Eur J Clin Microbiol Infect Dis 2008; 27:85-8.
25. Apisarnthanarak A, Kiratisin P, Saifon P, Kitphati R, Dejsirilert S, Mundy LM. Clinical and molecular epidemiology of communityonset, extended-spectrum ?-lactamase-producing Escherichia coli infections in Thailand: a case-case-control study. Am J Infect Control 2007; 35:606-12.
26. Moor CT, Roberts SA, Simmons G, et al. Extended-spectrum ?-lactamase (ESBL)-producing enterobacteria: factors associated with infection in the community setting, Auckland, New Zealand. J Hosp Infect 2008; 68:355-62.
27. Yumuk Z, Afacan G, Nicolas-Chanoine MH, Sotto A, Lavigne JP. Turkey: a further country concerned by community-acquired Escherichia coli clone O25-ST131 producing CTX-M-15. J Antimicrob Chemother 2008; 62:284-8.
28. Kariuki S, Revathi G, Corkill J, et al. Escherichia coli from communityacquired urinary tract infections resistant to fluoroquinolones and extended-spectrum ?-lactams. J Infect Dev Ctries 2007; 1:257-62.
29. Doi Y, Adams J, O'Keefe A, Quereshi Z, Ewan L, Paterson DL. Community-acquired extended-spectrum ?-lactamase producers, United States. Emerg Infect Dis 2007; 13:1121-3.
30. Freeman JT, Sexton DJ, Anderson DJ. Emergence of extendedspectrum ?-lactamase-producing Escherichia coli in community hospitals throughout North Carolina: a harbinger of a wider problem in the United States? Clin Infect Dis 2009; 49:e30-2.
31. Gaynes R. Health care-associated bloodstream infections: a change in thinking. Ann Intern Med 2002; 137:850-1.
32. Johnson JR, Johnston B, Clabots C, Kuskowski MA, Castanheira M. Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States. Clin Infect Dis 2010; 51:286-94.
33. Kim YA, Qureshi ZA, Adams-Haduch JM, Park YS, Shutt KA, Doi Y. Features of infections due to Klebsiella pneumoniae carbapenemaseproducing Escherichia coli: emergence of sequence type 131. Clin Infect Dis 2012; 55:224-31.
34. Clermont O, Lavollay M, Vimont S, et al. The CTX-M-15-producing Escherichia coli diffusing clone belongs to a highly virulent B2 phylogenetic subgroup. J Antimicrob Chemother 2008; 61: 1024-8.
35. Clark G, Paszkiewicz K, Hale J, et al. Genomic analysis uncovers a phenotypically diverse but genetically homogeneous Escherichia coli ST131 clone circulating in unrelated urinary tract infections. J Antimicrob Chemother 2012; 67:868-77.
36. Johnson JR, Porter SB, Zhanel G, Kuskowski MA, Denamur E. Virulence of Escherichia coli clinical isolates in a murine sepsis model in relation to sequence type ST131 status, fluoroquinolone resistance, and virulence genotype. Infect Immun 2012; 80:1554-62.
37. Lavigne JP, Vergunst AC, Goret L, et al. Virulence potential and genomic mapping of the worldwide clone Escherichia coli ST131. PLoS One 2012; 7:e34294.
38. Novais A, Pires J, Ferreira H, et al. Characterization of globally spread Escherichia coli ST131 isolates (1991 to 2010). Antimicrob Agents Chemother 2012; 56:3973-6.